AAF Wealth Management’s Acrivon Therapeutics ACRV Stock Holding History

AAF Wealth Management’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19K	Hold	10,678	–	–	0.01%	57
2026 Q1	$14.8K	Hold	10,678	–	–	0.01%	54
2025 Q4	$25.7K	Hold	10,678	–	–	0.01%	50
2025 Q3	$19.3K	Buy	+10,678	New	+$15K	0.01%	43
2025 Q2	–	Sell	-10,678	Closed	-$21.7K	–	48
2025 Q1	$21.7K	Hold	10,678	–	–	0.01%	47
2024 Q4	$64.3K	Hold	10,678	–	–	0.03%	47
2024 Q3	$74.7K	Hold	10,678	–	–	0.04%	44
2024 Q2	$61.9K	Hold	10,678	–	–	0.03%	46
2024 Q1	$76.3K	Hold	10,678	–	–	0.04%	43
2023 Q4	$52.5K	Hold	10,678	–	–	0.03%	50
2023 Q3	$102K	Hold	10,678	–	–	0.07%	44
2023 Q2	$138K	Buy	+10,678	New	+$129K	0.09%	49

Other funds holding ACRV

CBT

Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

AAF Wealth Management's ACRV Position: Q2 2026 in Review

AAF Wealth Management held its Acrivon Therapeutics (ACRV) position steady in Q2 2026 at 10,678 shares worth $19K. The position accounts for 0.01% of the portfolio, ranked #57.

AAF Wealth Management first reported a position in ACRV in Q2 2023 and has held it in 12 quarters since. The position peaked at $138K in Q2 2023. 3 funds tracked by Wall St. Rank hold ACRV as of Q2 2026.

AAF Wealth Management held 10,678 shares of Acrivon Therapeutics worth $19K as of Q2 2026.
AAF Wealth Management left its Acrivon Therapeutics share count unchanged in Q2 2026.
Acrivon Therapeutics made up 0.01% of AAF Wealth Management's portfolio in Q2 2026, its #57 holding.
AAF Wealth Management first reported a position in Acrivon Therapeutics in Q2 2023 and has held it in 12 quarters since.
AAF Wealth Management's Acrivon Therapeutics position peaked at $138K in Q2 2023.
3 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2026.

Based on AAF Wealth Management's 13F filing for Q2 2026, filed 17 Jul 2026.